Ovid Therapeutics (OVID) Receivables - Other (2016 - 2021)

Ovid Therapeutics has reported Receivables - Other for 5 years, with the latest figure at $1.0 million in Q1 2021.

• For the quarter ending Q1 2021, Receivables - Other rose 173.56% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2021 stood at $1.0 million (up 173.56% YoY), and the FY2020 full-year result was $141763.0, down 87.47% from the prior year.
• Receivables - Other for Q1 2021 stood at $1.0 million, up from $141763.0 in the prior quarter.
• The five-year high for Receivables - Other was $4.5 million in Q3 2018, with the low at $141763.0 in Q4 2020.
• Historically, Receivables - Other has averaged $1.2 million across 4 years, with a median of $836393.0 in 2020.
• Annual changes were most pronounced in 2020 — Receivables - Other tumbled 87.47% — and 2021, when it soared 173.56%.
• Ovid Therapeutics' Receivables - Other stood at $600104.0 in 2018, then jumped by 88.49% to $1.1 million in 2019, then plunged by 87.47% to $141763.0 in 2020, then soared by 622.18% to $1.0 million in 2021.
• The last three Receivables - Other figures came in at $1.0 million (Q1 2021), $141763.0 (Q4 2020), and $648995.0 (Q3 2020), per Business Quant data.